跳至主要内容
临床试验/NCT02420626
NCT02420626撤回不适用

Volcano Crux Vena Cava Filter Registry

Volcano Corporation3 个研究点 分布在 1 个国家开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
3
主要终点
Prevention of Pulmonary Embolism

研究概览

简要总结

The Crux Vena Cava Filter (VCF) Registry is a clinical study, sponsored by Volcano Corporation, to evaluate the short and long term performance and clinical outcomes of the Crux Vena Cava Filter System.

详细描述

The Crux VCF Registry is a non-randomized clinical study, sponsored by Volcano Corporation, to evaluate the short and long term performance and clinical outcomes of the Crux VCF System. The registry includes consecutive patients treated with the Crux VCF in a post-market (commercial) setting with data collection at the implant procedure through 2 years post implant or to filter retrieval, whichever comes first. Patients may also be enrolled (roll-in) from a previous Crux VCF implant within the previous 6 months. Follow up assessment will be performed at 6, 12 and 24 months post-implant and at the time of retrieval, if performed.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
19 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient is >18 years of age.
  • Patient or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent.
  • Scheduled for and receives a Crux VCF implant or;
  • Have previously had a Crux VCF implanted within the previous 6 months.

排除标准

  • Patient is scheduled for filter implant, but did not have a Crux VCF filter implanted due to anatomical exclusions or technical failures.
  • Patients unwilling or unable to comply with the protocol and provide informed consent.
  • Female patient of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to implantation and any retrieval procedure)
  • Patient is participating in another device or drug clinical trial that interferes with this protocol follow up schedule.

结局指标

主要结局

Prevention of Pulmonary Embolism

时间窗: 2 years

The primary objective is to evaluate the long term clinical outcomes of patients treated with the Crux VCF for the prevention of PE over a two year period or up to filter retrieval, whichever comes first.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验